vs
IONIS PHARMACEUTICALS INC（IONS）与Twist Bioscience Corp（TWST）财务数据对比。点击上方公司名可切换其他公司
IONIS PHARMACEUTICALS INC的季度营收约是Twist Bioscience Corp的2.0倍（$203.3M vs $103.7M），Twist Bioscience Corp净利率更高（-29.4% vs -112.8%，领先83.4%），Twist Bioscience Corp同比增速更快（16.9% vs -10.3%），Twist Bioscience Corp自由现金流更多（$-34.8M vs $-159.0M）
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
Twist Bioscience是总部位于美国南旧金山的上市生物技术企业，由艾米丽·勒普鲁斯特、比尔·班亚伊及比尔·佩克于2013年创立，专注于合成DNA及相关DNA产品的研发生产，服务覆盖多行业领域的客户需求。
IONS vs TWST — 直观对比
营收规模更大
IONS
是对方的2.0倍
$103.7M
营收增速更快
TWST
高出27.2%
-10.3%
净利率更高
TWST
高出83.4%
-112.8%
自由现金流更多
TWST
多$124.2M
$-159.0M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $203.3M | $103.7M |
| 净利润 | $-229.4M | $-30.5M |
| 毛利率 | 96.1% | 52.0% |
| 营业利润率 | -105.5% | -31.7% |
| 净利率 | -112.8% | -29.4% |
| 营收同比 | -10.3% | 16.9% |
| 净利润同比 | -119.8% | 3.4% |
| 每股收益（稀释后） | $-1.35 | $-0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IONSTWST
| Q4 25 | $203.3M | $103.7M | ||
| Q3 25 | $156.7M | — | ||
| Q2 25 | $452.0M | — | ||
| Q1 25 | $131.6M | — | ||
| Q4 24 | $226.6M | — | ||
| Q3 24 | $133.8M | — | ||
| Q2 24 | $225.3M | — | ||
| Q1 24 | $119.5M | — |
净利润IONSTWST
| Q4 25 | $-229.4M | $-30.5M | ||
| Q3 25 | $-128.6M | — | ||
| Q2 25 | $123.6M | — | ||
| Q1 25 | $-146.9M | — | ||
| Q4 24 | $-104.3M | — | ||
| Q3 24 | $-140.5M | — | ||
| Q2 24 | $-66.3M | — | ||
| Q1 24 | $-142.8M | — |
毛利率IONSTWST
| Q4 25 | 96.1% | 52.0% | ||
| Q3 25 | 98.5% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 98.9% | — | ||
| Q4 24 | 98.3% | — | ||
| Q3 24 | 99.2% | — | ||
| Q2 24 | 98.2% | — | ||
| Q1 24 | 98.2% | — |
营业利润率IONSTWST
| Q4 25 | -105.5% | -31.7% | ||
| Q3 25 | -102.2% | — | ||
| Q2 25 | 30.9% | — | ||
| Q1 25 | -111.6% | — | ||
| Q4 24 | -48.9% | — | ||
| Q3 24 | -111.1% | — | ||
| Q2 24 | -29.3% | — | ||
| Q1 24 | -125.1% | — |
净利率IONSTWST
| Q4 25 | -112.8% | -29.4% | ||
| Q3 25 | -82.1% | — | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | -111.6% | — | ||
| Q4 24 | -46.1% | — | ||
| Q3 24 | -105.0% | — | ||
| Q2 24 | -29.4% | — | ||
| Q1 24 | -119.5% | — |
每股收益（稀释后）IONSTWST
| Q4 25 | $-1.35 | $-0.50 | ||
| Q3 25 | $-0.80 | — | ||
| Q2 25 | $0.70 | — | ||
| Q1 25 | $-0.93 | — | ||
| Q4 24 | $-0.66 | — | ||
| Q3 24 | $-0.95 | — | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.98 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.7B | $197.9M |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $489.1M | $456.1M |
| 总资产 | $3.5B | $638.1M |
| 负债/权益比越低杠杆越低 | 3.71× | — |
8季度趋势，按日历期对齐
现金及短期投资IONSTWST
| Q4 25 | $2.7B | $197.9M | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.2B | — |
总债务IONSTWST
| Q4 25 | $1.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IONSTWST
| Q4 25 | $489.1M | $456.1M | ||
| Q3 25 | $618.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $475.7M | — | ||
| Q4 24 | $588.4M | — | ||
| Q3 24 | $662.5M | — | ||
| Q2 24 | $263.7M | — | ||
| Q1 24 | $296.5M | — |
总资产IONSTWST
| Q4 25 | $3.5B | $638.1M | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $2.8B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.8B | — |
负债/权益比IONSTWST
| Q4 25 | 3.71× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-137.7M | $-24.8M |
| 自由现金流经营现金流 - 资本支出 | $-159.0M | $-34.8M |
| 自由现金流率自由现金流/营收 | -78.2% | -33.5% |
| 资本支出强度资本支出/营收 | 10.5% | 9.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-320.0M | — |
8季度趋势，按日历期对齐
经营现金流IONSTWST
| Q4 25 | $-137.7M | $-24.8M | ||
| Q3 25 | $-131.4M | — | ||
| Q2 25 | $151.3M | — | ||
| Q1 25 | $-150.8M | — | ||
| Q4 24 | $-116.1M | — | ||
| Q3 24 | $-115.0M | — | ||
| Q2 24 | $-119.9M | — | ||
| Q1 24 | $-149.9M | — |
自由现金流IONSTWST
| Q4 25 | $-159.0M | $-34.8M | ||
| Q3 25 | $-136.7M | — | ||
| Q2 25 | $139.0M | — | ||
| Q1 25 | $-163.4M | — | ||
| Q4 24 | $-141.6M | — | ||
| Q3 24 | $-124.0M | — | ||
| Q2 24 | $-126.1M | — | ||
| Q1 24 | $-154.4M | — |
自由现金流率IONSTWST
| Q4 25 | -78.2% | -33.5% | ||
| Q3 25 | -87.2% | — | ||
| Q2 25 | 30.8% | — | ||
| Q1 25 | -124.1% | — | ||
| Q4 24 | -62.5% | — | ||
| Q3 24 | -92.7% | — | ||
| Q2 24 | -56.0% | — | ||
| Q1 24 | -129.2% | — |
资本支出强度IONSTWST
| Q4 25 | 10.5% | 9.6% | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.8% | — |
现金转化率IONSTWST
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
